(Formerly known as Central Clinical School)
 |
The BiVACOR Total Artificial Heart shown in the chest cavity (left) and transparent image demonstrating the capacity to support the whole heart (right). |
Monash University has partnered with a United States-based company, ModifyHealth, to raise further awareness in the US of the FODMAP diet protocol and the Monash University FODMAP Diet App, which have helped millions of people manage irritable bowel syndrome (IBS). The partnership will increase engagement with US consumers and healthcare providers, and expand awareness of the latest research and developments of the FODMAP diet protocol.
 |
| Dr Scott Kolbe, senior author on the paper analysing the association between nerve damage and gait impairment in MS patients. |
Findings published in the journal, Brain Communications, have revealed that patients with Multiple Sclerosis (MS) who had gait and lower limb motor control impairments also had corresponding axonal (parts of nerve cells) loss in major tracts in the brain which control sensing and movement response.
Damage that occurs in MS (e.g. inflammation, demyelination and injury and loss of axons) results in upper and lower motor impairments in the majority of patients with symptoms including problems with balance and walking, muscle weakness and spasticity. These impairments have a considerable impact on their daily living and quality of life, in particular on their employment and study.
See more about A/Prof Wright's research at:
The University Professorial Promotion Committee noted A/Prof Hagemeyer's "significant contribution to the University in the areas of academic activity: research, engagement and education. In particular, the Committee noted [his] contributions to leadership and strong translational work in [his] field."
A/Prof Hagemeyer was President of the Australian Society for Medical Research during 2020. See more about his research in the Australian Centre for Blood Diseases. Follow the group on their channels:
Monash University has launched world-first technology that can detect magnetic nanoparticles anywhere in the body, enabling enhanced medical applications such as tracking of beneficial CAR-T cells during cancer therapy.
The new technology was funded through an ARC LIEF grant with contributions from Monash University and RMIT, and combines Magnetic Particle Imaging (MPI) with Computed Tomography (CT) and Hyperthermia capabilities for preclinical, in vivo research. It is located at the Monash Alfred campus and is operated by the Alfred Research Alliance-Monash Biomedical Imaging (ARA-MBI) platform.
 |
| 2020 CCS GEDI committee (pre-COVID) |
